Global Glycomics/Glycobiology Market Size, Forecast, and Trend Highlights Over 2025-2037
Glycomics/Glycobiology Market size was valued at USD 2.1 billion in 2024 and is projected to reach USD 10.2 billion by the end of 2037, rising at a CAGR of 13.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of glycomics/glycobiology is estimated at USD 2.3 billion.
The global market is growing exponentially, fueled by its extensive patient pool that is necessitating therapeutics for oncology, immunology, and rare metabolic disorders. For instance, in 2023, the article published by the National Institute of Health states that more than 1.6 million cases of cancer were detected annually in the U.S., with glycan-based biomarkers playing a critical role in the treatment procedure. Meanwhile, on the economic front, the PPI and CPI of glycobiology products rose by 6.4% and 5.1% owing to high costs of raw materials and regulatory compliance. Hence, this patient pool, coupled with the demand for precision medicine, has shaped the market growth across all nations.
The global trade in terms of glycomics and glycobiology is appreciably carried out by emerging nations. In this regard, the WTO in 2024 states that more than 75% of glycan exports are led by the U.S., Germany, China, and Japan. Besides, it is reported that the U.S. imports nearly USD 321 million worth of glycobiology enzymes and reagents mainly from Germany and Switzerland. Furthermore, the investments in research have drawn the interest of key players to invest in efficient formulations, as it reached USD 2.2 billion, thereby uplifting market development.
Glycomics/Glycobiology Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing prevalence of chronic diseases: There is a growing burden of chronic diseases, such as cancer and metabolic disorders, which efficiently drives business in the market. In this regard, RKI in 2024 reported that in Germany, nearly 2.5 million patients required glycan-based diagnostics in 2025, which is a 41% rise from 2020. Besides, WHO states that in Europe, there will be a heightened demand for glycotherapeutics by 2030. Therefore, this expanding demand necessitates the requirement for glycomics or glycobiology therapeutics.
- Progression in glycomic innovations: The strategic collaborations between pharmaceutical firms and innovations in glycobiology therapeutics are yet another driver in the market. In this regard, in 2023, Thermo Fisher acquired GlycoSelect, which enhanced its product portfolio significantly by capturing an increased market share of 14%. Besides, in 2024, Agilent announced a partnership with 20 EU-based hospitals to introduce AI-based glycomics platforms, which reduce lab costs by 30%, thereby reflecting an increased market adoption.
Manufacturer Strategies Strengthening Glycomics/Glycobiology Market Positions
The global market is gaining traction due to the strategies opted by manufacturers to strengthen their market positions. Key trends undertaken by the firms include market innovation, collaborations, and expansions in rapidly emerging markets. In this regard, the U.S. FDA’s Biosimilars Research Awards highly support the innovation in the biosimilar sector, aiding in cost-effective alternatives, expanding the market reach internationally. These factors are anticipated to contribute to the market adoption, thereby creating revenue opportunities for global market players.
Revenue Opportunities for Glycomics/Glycobiology Manufacturers
|
Company/Region |
Strategy |
Impact on Market Position |
Estimated Revenue Impact |
|
Novo Nordisk |
Expansion of GLP-1 drug portfolio |
Increased market share in diabetes treatment |
$9.3 billion |
|
FDA Biosimilars Research Awards |
Support for biosimilar development |
Facilitation of affordable treatment options |
$23.7 billion |
|
Germany |
Projected increase in type 2 diabetes prevalence |
Expanded patient pool for glycomics-based therapies |
N/A |
|
U.S. Healthcare Spending |
Increased allocation to prescription drugs |
Enhanced market potential for glycomics manufacturers |
$5.1 trillion |
Feasible Expansion Models Shaping the Glycomics/Glycobiology Market
The market is witnessing remarkable growth, critically influenced by different sorts of expansion models undertaken to enhance accessibility and affordability. It is reported that there is a heightened demand for advanced diagnostic tools such as glycomic-based solutions in India’s pharmaceutical sector, due to which it is estimated to reach USD 135 billion by 2030. Furthermore, this robust market ecosystem intends to support glycomic manufacturers, allowing them to collaborate with domestic healthcare facilities, thereby denoting a positive market outlook.
Feasibility Models for Glycomics Market Expansion
|
Model Type |
Region |
Strategy Description |
Estimated Revenue Impact (USD) |
|
Partnership Model |
India |
Collaboration with local healthcare providers to distribute glycomics-based diagnostics |
14% increase from 2022 to 2024 |
|
Government Funding Model |
Canada |
Utilization of grants like GlycoNet's $16.3 million funding to support research initiatives |
$16.5 million (2020) |
|
Market Expansion Model |
USA |
Expansion into emerging markets through strategic partnerships and product innovation |
$9.5 billion (2023) |
|
Policy Support Model |
USA |
Implementation of policies like the Inflation Reduction Act to cap insulin costs at $35 for Medicare beneficiaries |
$36.2 billion (2023) |
Challenge
- Increasing equipment and operational costs: This factor poses a significant challenge for the market upliftment across all nations. The high cost associated with specialized equipment such as mass spectrometers and glycan microarrays hinders expanded access for glycomics researchers. Besides, it is reported that glycomics analysis services can cost between USD 100 to USD 600 per sample, making it challenging for smaller institutions to invest in this sector.
Glycomics/Glycobiology Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.5% |
|
Base Year Market Size (2024) |
USD 2.1 billion |
|
Forecast Year Market Size (2037) |
USD 10.2 billion |
|
Regional Scope |
|
Glycomics/Glycobiology Segmentation
Product (Enzymes, Kits & Reagents, Instruments)
Based on product, the kits & reagents segment is expected to hold the highest share of 38.8% in the glycomics/glycobiology market by the end of 2037. The dominance of the segment is responsible for its increased applications in cancer and infectious disease screening procedures, and growing adoption in diagnostic labs. In this regard, NCEZID reported that there is a 25% increase in the volume of diagnostic testing in 2024, reflecting a positive market demand. Besides, the U.S. FDA states that in 2023 alone, 14 new glycan analysis kits were approved, which is a 42% increase since 2022. The regulatory support, coupled with diagnostic applications, reinforces dominance in the segment.
Application (Drug Discovery & Development, Diagnostics, Therapeutics)
Based on the application, the drug discovery and development segment is projected to account for a lucrative share of 34.6% in the glycomics/glycobiology market during the forecast period. The growth in the segment is subject to increased public healthcare investments. In this regard, NIH in 2024 reported that it allocated USD 670 million for glycan drug development, with more than 60% towards glycosylation engineering of biologic therapeutics. Besides, the approval of 80% of new biologics requires glycan analysis for characterization protocols, thus increasing the demand for glycobiology products.
Our in-depth analysis of the glycomics/glycobiology market includes the following segments:
|
Product |
|
|
Application |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportGlycomics/Glycobiology Industry– Regional Synopsis
North America Market Analysis
The glycomics/glycobiology market in North America is expected to dominate with a notable share of 45.7% during the forecast timeline, i.e., from 2025 to 2037. The region benefits from increased government funding, advanced research infrastructure, and a growing focus on precision medicine. Besides, in the U.S, the federal healthcare systems such as the CDC and AHRQ have enhanced their allocations towards glycomic research to aiming to facilitate advancements in diagnostic and therapeutic innovations. In this regard, Medicare increased its spending by 18% from 2020 to 2024, expanding its access to aging populations, thus accelerating adoption.
The Canada market is poised for growth, extensively supported by government and provincial system support, fueling innovation and applications. In this regard, the federal government in the country launched a Canada Genomic Strategy, which contributed USD 175.2 million over the last seven years to aid in glycomic applications. Besides, British Columbia has enhanced their investment to USD 2.4 million to encourage regional innovations. Hence, these collaborations between provincial governments and private sector partnerships are accelerating the development of glycomics diagnostics and therapeutics.
Asia Pacific Market Statistics
The glycomics/glycobiology market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline, i.e., 2025-2037. The growth in the region is fueled by the increasing investments by governments, a vast consumer base, and ongoing technological breakthroughs in the biotechnology sector. Countries such as Japan, China, India, Malaysia, and South Korea extend their support, each with a unique strategy, making a huge contribution to the regional market. Collectively, these countries are intensifying their healthcare sector, thereby expanding access to glycomic-based solutions.
China's market is gaining immense exposure due to its large patient population and government-backed healthcare initiatives. Besides, the National Medical Products Administration has appreciably improved both approval and adoption of glycomics-based treatment procedures. Additionally, in 2023, more than 1.4 million patients were diagnosed with conditions necessitating glycomics and associated interventions. Furthermore, the government expenditure for glycomics increased by 15% over the last five years, further fostering a favorable business environment.
Companies Dominating the Glycomics/Glycobiology Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Companies involved in the global market are unfolding remarkable growth opportunities, seeking support from regulatory frameworks. In this regard, the U.S. and Europe-based firms are focusing on biopharmaceutical collaborations to expand their market share. Thermo Fisher and Agilent are leading the market through AI-based glycan platforms that have resulted in a substantial market share reflecting technological adoption. Besides the focus on affordable diagnostics coupled with mergers and acquisitions collectively support the market landscape in this sector.
Here is the list of some prominent players in the industry:
|
Company Name |
Country |
Market Share (2024) |
|
Thermo Fisher Scientific |
USA |
20% |
|
Agilent Technologies |
USA |
15% |
|
Merck KGaA |
Germany |
12% |
|
Waters Corporation |
USA |
10% |
|
Shimadzu Corporation |
Japan |
9% |
|
Bruker Corporation |
USA |
xx% |
|
Danaher Corporation |
USA |
xx% |
|
Takara Bio |
Japan |
xx% |
|
Ludger Ltd |
UK |
xx% |
|
New England Biolabs |
USA |
xx% |
|
S-BIO |
South Korea |
xx% |
|
ProZyme |
USA |
xx% |
|
GlycoSolutions |
Australia |
xx% |
|
Dextra Laboratories |
UK |
xx% |
|
RayBiotech |
USA |
xx% |
|
Z Biotech |
Germany |
xx% |
|
Bio-Techne |
USA |
xx% |
|
Premas Biotech |
India |
xx% |
|
GlycoNex |
Taiwan |
xx% |
|
Malaysian Glycomics Consortium |
Malaysia |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In May 2024, Agilent Technologies launched the GlycoBiosign 2.0 Kit, the first FDA-cleared glycan biomarker kit for early pancreatic cancer detection with 94% diagnostic accuracy in NIH-funded trials.
- In March 2024, Thermo Fisher Scientific launched the GlycoTrack 5000 System, an automated high-throughput glycan analyzer for biopharma QC. It captured 20% of the glycan analysis instrument market within 6 months, per FDA 510(k) clearance data.
Author Credits: Radhika Pawar
- Report ID: 2635
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
